Literature DB >> 33351151

Hodgkin Lymphoma Survivors: We Need to Do Better.

Tara O Henderson1, Kevin C Oeffinger2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33351151      PMCID: PMC8168106          DOI: 10.1093/jnci/djaa196

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.

Authors:  Paul J Bröckelmann; Helen Goergen; Ulrich Keller; Julia Meissner; Rainer Ordemann; Teresa V Halbsguth; Stephanie Sasse; Martin Sökler; Andrea Kerkhoff; Stephan Mathas; Andreas Hüttmann; Matthias Bormann; Andreas Zimmermann; Jasmin Mettler; Michael Fuchs; Bastian von Tresckow; Christian Baues; Andreas Rosenwald; Wolfram Klapper; Carsten Kobe; Peter Borchmann; Andreas Engert
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

Review 2.  Models for delivering survivorship care.

Authors:  Kevin C Oeffinger; Mary S McCabe
Journal:  J Clin Oncol       Date:  2006-11-10       Impact factor: 44.544

Review 3.  Damocles' syndrome revisited: Update on the fear of cancer recurrence in the complex world of today's treatments and survivorship.

Authors:  Margaret Cupit-Link; Karen L Syrjala; Shahrukh K Hashmi
Journal:  Hematol Oncol Stem Cell Ther       Date:  2018-02-19

4.  Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.

Authors:  Simone de Vries; Michael Schaapveld; Cécile P M Janus; Laurien A Daniëls; Eefke J Petersen; Richard W M van der Maazen; Josée M Zijlstra; Max Beijert; Marten R Nijziel; Karijn M S Verschueren; Leontien C M Kremer; Anna M van Eggermond; Pieternella J Lugtenburg; Augustinus D G Krol; Judith M Roesink; Wouter J Plattel; Dick Johan van Spronsen; Gustaaf W van Imhoff; Jan Paul de Boer; Berthe M P Aleman; Flora E van Leeuwen
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 13.506

5.  Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Alex F Herrera; Alison J Moskowitz; Nancy L Bartlett; Julie M Vose; Radhakrishnan Ramchandren; Tatyana A Feldman; Ann S LaCasce; Stephen M Ansell; Craig H Moskowitz; Keenan Fenton; Carol Anne Ogden; David Taft; Qu Zhang; Kazunobu Kato; Mary Campbell; Ranjana H Advani
Journal:  Blood       Date:  2017-12-11       Impact factor: 25.476

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.